Myung In Pharm Co

Myung In Pharm Co FCF per Share

The Free Cash Flow per Share of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 3,199.59 KRW. In the previous year, Free Cash Flow per Share was 4,888.92 KRW — a change of -34.55% (lower).

FCF per Share

3,199.59KRW

YoY

-34.55%

Last updated:

Free Cash Flow per Share of Myung In Pharm Co is 2025 3,199.59 KRW. Free Cash Flow per Share of Myung In Pharm Co was 2024 4,888.92 KRW. It decreases by -34.55% lower compared to the previous year.

The Myung In Pharm Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2022
4,181.16 KRW
Jan 1, 2023
4,888.92 KRW
Jan 1, 2025
3,199.59 KRW
The Myung In Pharm Co FCF per Share history
YEARFCF per ShareYoY
3,199.59KRW-34.55%
4,888.92KRW+16.93%
4,181.16KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

Free Cash Flow per Share of Myung In Pharm Co is 3,199.59 KRW in 2025.

Free Cash Flow per Share of Myung In Pharm Co changed from 4,888.92 KRW to 3,199.59 KRW, representing a -34.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co